ImmuPharma PLC
  • Announcements
  • About Us
    • About Us
    • Our Team
    • Board of Directors
  • Our Science
    • Our Science
    • ImmuPharma Biotech
    • Key Clinical Investigators
  • Pipeline
    • Pipeline
    • Autoimmunity & Inflammation
    • Anti-Infectives
  • Partnerships & Collaborations
  • Investors
    • Investors
    • AIM Rule 26 Information
    • Regulatory News
    • Corporate Governance
    • Board of Directors
    • Annual Reports
    • Analyst Research
    • Interviews
    • Professional advisers
    • Email Alerts
  • Contact
Archives
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
December 22, 2016

Update on Lupuzor™ Pivotal Phase III Study – Patient Recruitment Completed

Read More
November 16, 2016

Update on Cancer Compound IPP-204106 ‘Nucant’

Read More
November 09, 2016

Notification of Major Interest by Legal & General

Read More
October 26, 2016

TR1 Notification of Major Interest

Read More
October 21, 2016

Proposed Accelerated Bookbuild for Vendor Placing and Issue of Equity

Read More
October 21, 2016

Close of Accelerated Bookbuild

Read More
September 30, 2016

INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2016

Read More
September 14, 2016

Update on Lupuzor’s Pivotal Phase III Study – 11 US Sites Now Open, 5 European Countries Now Recruiting

Read More
September 07, 2016

ImmuPharma Invited to Open an Additional Site in Mauritius

Read More
September 07, 2016

ImmuPharma Invited to Open an Additional Site in Mauritius

Read More
June 20, 2016

Northland Capital Appointed as Joint Broker

Read More
June 08, 2016

Immupharma Hosts Lupuzor ™ Symposium with Lupuzor’s™ Inventor, Prof. Sylviane Muller

Read More
  • 1
  • 2
  • 3
  • Keep up-to-date with email alerts

  • @immupharma

Aim Rule 26 Contact informationDisclaimerPrivacy PolicySite map

© ImmuPharma PLC 2005-2022 | All rights reserved